Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 20, 2018. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a single transaction involving American Depositary Shares (ADSs).
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ADSs (Dividend Re-investment) |
| Instrument | American Depositary Shares (ISIN: US37733W1053) |
| Transaction Price | $40.534 |
| Transaction Volume | 35,011 shares |
| Transaction Date | April 12, 2018 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a routine acquisition of shares by a Principal Director or Manager (PDMR) under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed following the re-investment of dividends paid to shareholders on April 12, 2018.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Mr. B McNamara, CEO of Consumer Healthcare.
- Transaction Nature: The purchase was not a direct cash buy but an acquisition of ADSs following the re-investment of dividends.
- Plan Details: The shares were held in the Deferred Annual Bonus Plan Post-Tax.
- Market Data: The transaction occurred on the NYSE at a price of $40.534 per share.